Yuma Clinical Trials | Yuma, AZ
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult participants with obesity or overweight and type 2 diabetes. The study will last about 77 weeks and may include up to 22 visits.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Have a body mass index (BMI) ≥27.0 kilogram/square meter (kg/m²).
Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight.
Have a diagnosis of Type 2 Diabetes (T2D), with HbA1c ≥7% (≥53 mmol/mol) to ≤10% (86 mmol/mol) and are on stable treatment for T2D for at least 90 days prior to screening, consisting of:
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
1,500 participants in 4 patient groups, including a placebo group
Loading...
Central trial contact
There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal